Aldafermin reduces liver fat, improves fibrosis in NASH

Aldafermin decreased liver fat and trended toward fibrosis improvement among patients with non-alcoholic steatohepatitis, according to a study published in Gastroenterology.“Finally, this is the first report to date evaluating the longitudinal change in NASH histology in response to a therapeutic agent in 24 weeks, the shortest time period for a placebo-controlled trial thus far,” Stephen A. Harrison, MD, from the Radcliffe department of medicine at the University of Oxford and colleagues wrote. “The speed and magnitude at which such histological change can happen indicateRead More

Share on facebook
Share on twitter
Share on linkedin